Literature DB >> 35789022

Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.

Adela Ramirez-Torres1, Allison L Reagan2,3, Lauren E Howard2,3, Emily Wiggins3, Adriana C Vidal1, Junxiang Wan4, Brendan Miller4, Stephen J Freedland1,3, Pinchas Cohen4.   

Abstract

INTRODUCTION: The mitochondrial genome has small open reading frames (sORF) which produce measurable mitochondrial-derived peptides (MDPs), including humanin, SHLP2, and MOTS-c. Previously, among men undergoing prostate biopsy, we found higher serum SHLP2 was linked with lower prostate cancer (PC) risk in European American men (EAM), while null associations were found in African American men (AAM). Here, in different patients undergoing prostate biopsy, we tested the link between SHLP2, humanin and MOTS-c and PC risk by race.
METHODS: Plasma SHLP2, humanin, and MOTS-c were measured in 198 men (50/49 EAM/AAM cases; 50/49 EAM/AAM controls) undergoing biopsy. Logistic and multinomial regression models tested associations between each MDP and PC diagnosis, low-grade (grade group, GG1) and high-grade (GG2-5). Models were adjusted for age, body mass index, digital rectal examination, and prostate specific antigen (PSA). We tested interactions between MDPs and race.
RESULTS: Among controls, humanin was similar by race (p = 0.60), but both SHLP2 (p = 0.007) and MOTS-c (p = 0.026) were lower in AAM controls versus EAM controls. Among EAM, higher MDP values were associated with lower PC risk (all p ≤ 0.001), with null associations in AAM (all p-interactions ≤ 0.01). Similarly, higher MDP expression was associated with decreased risk of low- and high-grade PC in EAM (all p ≤ 0.005) with null associations in AAM.
CONCLUSIONS: Higher MDP levels were associated with lower PC risk in EAM but not AAM. Generally, AAM controls had lower MDP levels. These data support MDPs and mitochondrial dysfunction in PC, suggesting greater dysfunction in AAM may contribute to excess PC risk. Future larger studies are needed to confirm these results.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  disparities; mitochondrial dysfunction; mitochondrial genome; mitochondrial-derived peptides (MDPs); prostate cancer

Mesh:

Substances:

Year:  2022        PMID: 35789022      PMCID: PMC9388542          DOI: 10.1002/pros.24398

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.012


  32 in total

1.  Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley.

Authors:  Dipendra Raj Pandeya; Ankush Mittal; Brijesh Sathian; Bibek Bhatta
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents.

Authors:  Yung-Ping Chin; Jyotsna Keni; Junxiang Wan; Hemal Mehta; Francine Anene; Yue Jia; Yan-He Lue; Ronald Swerdloff; Laura J Cobb; Christina Wang; Pinchas Cohen
Journal:  Endocrinology       Date:  2013-07-08       Impact factor: 4.736

3.  Effect of mtDNA mutation on tumor malignant degree in patients with prostate cancer.

Authors:  Jian Jun Yu; Tao Yan
Journal:  Aging Male       Date:  2010-09       Impact factor: 5.892

4.  Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy.

Authors:  Vittorio Fasulo; Janet E Cowan; Martina Maggi; Samuel L Washington; Hao G Nguyen; Katsuto Shinohara; Massimo Lazzeri; Paolo Casale; Peter R Carroll
Journal:  Eur Urol Oncol       Date:  2020-10-14

5.  The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort.

Authors:  Alexis R Gaines; Elizabeth L Turner; Patricia G Moorman; Stephen J Freedland; Christopher J Keto; Megan E McPhail; Delores J Grant; Adriana C Vidal; Cathrine Hoyo
Journal:  Cancer Causes Control       Date:  2014-05-31       Impact factor: 2.506

6.  MOTS-c: an equal opportunity insulin sensitizer.

Authors:  Su-Jeong Kim; Brendan Miller; Hiroshi Kumagai; Kelvin Yen; Pinchas Cohen
Journal:  J Mol Med (Berl)       Date:  2019-02-20       Impact factor: 4.599

7.  The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.

Authors:  Su-Jeong Kim; Brendan Miller; Hemal H Mehta; Jialin Xiao; Junxiang Wan; Thalida E Arpawong; Kelvin Yen; Pinchas Cohen
Journal:  Physiol Rep       Date:  2019-07

8.  Oxidative Stress and Antioxidant Status in High-Risk Prostate Cancer Subjects.

Authors:  Sanjeev Shukla; Janmejai K Srivastava; Eswar Shankar; Rajnee Kanwal; Akbar Nawab; Haripaul Sharma; Natarajan Bhaskaran; Lee E Ponsky; Pingfu Fu; Gregory T MacLennan; Sanjay Gupta
Journal:  Diagnostics (Basel)       Date:  2020-02-27

9.  Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk.

Authors:  Jialin Xiao; Lauren Howard; Junxiang Wan; Emily Wiggins; Adriana Vidal; Pinchas Cohen; Stephen J Freedland
Journal:  Oncotarget       Date:  2017-08-10

10.  Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Authors:  David V Conti; Burcu F Darst; Lilit C Moss; Edward J Saunders; Xin Sheng; Alisha Chou; Fredrick R Schumacher; Ali Amin Al Olama; Sara Benlloch; Tokhir Dadaev; Mark N Brook; Ali Sahimi; Thomas J Hoffmann; Atushi Takahashi; Koichi Matsuda; Yukihide Momozawa; Masashi Fujita; Kenneth Muir; Artitaya Lophatananon; Peggy Wan; Loic Le Marchand; Lynne R Wilkens; Victoria L Stevens; Susan M Gapstur; Brian D Carter; Johanna Schleutker; Teuvo L J Tammela; Csilla Sipeky; Anssi Auvinen; Graham G Giles; Melissa C Southey; Robert J MacInnis; Cezary Cybulski; Dominika Wokołorczyk; Jan Lubiński; David E Neal; Jenny L Donovan; Freddie C Hamdy; Richard M Martin; Børge G Nordestgaard; Sune F Nielsen; Maren Weischer; Stig E Bojesen; Martin Andreas Røder; Peter Iversen; Jyotsna Batra; Suzanne Chambers; Leire Moya; Lisa Horvath; Judith A Clements; Wayne Tilley; Gail P Risbridger; Henrik Gronberg; Markus Aly; Robert Szulkin; Martin Eklund; Tobias Nordström; Nora Pashayan; Alison M Dunning; Maya Ghoussaini; Ruth C Travis; Tim J Key; Elio Riboli; Jong Y Park; Thomas A Sellers; Hui-Yi Lin; Demetrius Albanes; Stephanie J Weinstein; Lorelei A Mucci; Edward Giovannucci; Sara Lindstrom; Peter Kraft; David J Hunter; Kathryn L Penney; Constance Turman; Catherine M Tangen; Phyllis J Goodman; Ian M Thompson; Robert J Hamilton; Neil E Fleshner; Antonio Finelli; Marie-Élise Parent; Janet L Stanford; Elaine A Ostrander; Milan S Geybels; Stella Koutros; Laura E Beane Freeman; Meir Stampfer; Alicja Wolk; Niclas Håkansson; Gerald L Andriole; Robert N Hoover; Mitchell J Machiela; Karina Dalsgaard Sørensen; Michael Borre; William J Blot; Wei Zheng; Edward D Yeboah; James E Mensah; Yong-Jie Lu; Hong-Wei Zhang; Ninghan Feng; Xueying Mao; Yudong Wu; Shan-Chao Zhao; Zan Sun; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Catharine M L West; Neil Burnet; Gill Barnett; Christiane Maier; Thomas Schnoeller; Manuel Luedeke; Adam S Kibel; Bettina F Drake; Olivier Cussenot; Géraldine Cancel-Tassin; Florence Menegaux; Thérèse Truong; Yves Akoli Koudou; Esther M John; Eli Marie Grindedal; Lovise Maehle; Kay-Tee Khaw; Sue A Ingles; Mariana C Stern; Ana Vega; Antonio Gómez-Caamaño; Laura Fachal; Barry S Rosenstein; Sarah L Kerns; Harry Ostrer; Manuel R Teixeira; Paula Paulo; Andreia Brandão; Stephen Watya; Alexander Lubwama; Jeannette T Bensen; Elizabeth T H Fontham; James Mohler; Jack A Taylor; Manolis Kogevinas; Javier Llorca; Gemma Castaño-Vinyals; Lisa Cannon-Albright; Craig C Teerlink; Chad D Huff; Sara S Strom; Luc Multigner; Pascal Blanchet; Laurent Brureau; Radka Kaneva; Chavdar Slavov; Vanio Mitev; Robin J Leach; Brandi Weaver; Hermann Brenner; Katarina Cuk; Bernd Holleczek; Kai-Uwe Saum; Eric A Klein; Ann W Hsing; Rick A Kittles; Adam B Murphy; Christopher J Logothetis; Jeri Kim; Susan L Neuhausen; Linda Steele; Yuan Chun Ding; William B Isaacs; Barbara Nemesure; Anselm J M Hennis; John Carpten; Hardev Pandha; Agnieszka Michael; Kim De Ruyck; Gert De Meerleer; Piet Ost; Jianfeng Xu; Azad Razack; Jasmine Lim; Soo-Hwang Teo; Lisa F Newcomb; Daniel W Lin; Jay H Fowke; Christine Neslund-Dudas; Benjamin A Rybicki; Marija Gamulin; Davor Lessel; Tomislav Kulis; Nawaid Usmani; Sandeep Singhal; Matthew Parliament; Frank Claessens; Steven Joniau; Thomas Van den Broeck; Manuela Gago-Dominguez; Jose Esteban Castelao; Maria Elena Martinez; Samantha Larkin; Paul A Townsend; Claire Aukim-Hastie; William S Bush; Melinda C Aldrich; Dana C Crawford; Shiv Srivastava; Jennifer C Cullen; Gyorgy Petrovics; Graham Casey; Monique J Roobol; Guido Jenster; Ron H N van Schaik; Jennifer J Hu; Maureen Sanderson; Rohit Varma; Roberta McKean-Cowdin; Mina Torres; Nicholas Mancuso; Sonja I Berndt; Stephen K Van Den Eeden; Douglas F Easton; Stephen J Chanock; Michael B Cook; Fredrik Wiklund; Hidewaki Nakagawa; John S Witte; Rosalind A Eeles; Zsofia Kote-Jarai; Christopher A Haiman
Journal:  Nat Genet       Date:  2021-01-04       Impact factor: 38.330

View more
  1 in total

1.  MDPs and racial differences in prostate cancer.

Authors:  Maria Chiara Masone
Journal:  Nat Rev Urol       Date:  2022-09       Impact factor: 16.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.